Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
On Monday, Stifel analysts began coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX), assigning the biopharmaceutical company a Buy rating and setting a price target of $36.00. According to InvestingPro data, analyst targets for AVTX range from $18 to $48, with the company currently trading at $7.63, suggesting significant upside potential. The stock appears undervalued based on InvestingPro’s Fair Value analysis. The firm’s positive stance is rooted in the potential of the Hidradenitis Suppurativa (HS) market and the promising data surrounding AVTX’s leading candidate, AVTX-009.
AVTX-009, an IL-1β monoclonal antibody, is seen as a strong contender in the HS treatment space, leveraging data from a related compound by AbbVie (NYSE:ABBV), Lutikizumab, which targets both IL-1α and IL-1β. Stifel’s analysis suggests that AVTX-009’s heightened potency and selectivity for IL-1β could lead to improved efficacy in treating HS.
The analysts underscored the significance of the HS market, noting strategic interest in the area and the potential for AVTX-009 to stand out due to its specialized mechanism. They anticipate that the upcoming Phase 2 data, expected in the 2026 timeframe, will further clarify the treatment’s potential.
Avalo Therapeutics’ financial position is also highlighted, with the company reportedly ending 2024 with approximately $135 million in cash and equivalents. This positions the company with sufficient capital to continue operations into 2027. InvestingPro analysis confirms the company’s strong liquidity position, with a current ratio of 19.96x and more cash than debt on its balance sheet. While the company isn’t currently profitable, these metrics suggest solid financial stability. (Get access to 8 more exclusive InvestingPro Tips for AVTX and comprehensive financial analysis with an InvestingPro subscription.) The analysts also mentioned that the next 12 months could see beneficial external news flow for HS, which may serve as an additional positive factor for Avalo Therapeutics.
Moreover, Stifel pointed out that there is an opportunity for AVTX-009 to be applied to other inflammatory conditions where IL-1 blockade has been validated, suggesting a broader scope for the company’s therapeutic strategy. This optionality adds another layer to the investment case for Avalo Therapeutics as it progresses through its clinical development phases. The company’s market capitalization currently stands at $79.45 million, with the stock showing strong momentum, delivering a 57% return over the past year despite recent market volatility. Investors should note that the company’s next earnings report is scheduled for March 28, which could provide additional clarity on its development progress.
In other recent news, Avalo Therapeutics Inc. has been the focus of attention following new analyses from major firms. Oppenheimer reaffirmed its Outperform rating for Avalo, setting a price target of $35.00, citing a notable increase in net cash, approximately $68 million, from recent warrant exercises. The firm also highlighted the ongoing Phase 2 LOTUS trial for AVTX-009, aimed at treating hidradenitis suppurativa, with top line data expected by 2026. Avalo’s financial stability is underscored by cash reserves projected to sustain operations until 2027. Oppenheimer noted the strategic hiring of a new Chief Strategy Officer as a positive development, reinforcing the company’s leadership.
Piper Sandler initiated coverage with an Overweight rating and a higher price target of $48.00, suggesting the company is undervalued with its current market capitalization around $70 million. The firm expressed a high probability of success for AVTX-009, emphasizing its potential in the large market for hidradenitis suppurativa treatments. Piper Sandler pointed out Avalo’s competitive advantage due to its differentiated dosing schedules for AVTX-009. Both firms’ analyses reflect a positive outlook on Avalo’s future performance and therapeutic advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.